Targeting peptide SP94 midified DSPE-PEG micelles for enhanced hepatocellular carcinoma therapy

• 作 者: XiangtingZhuang;YulingBao;YuanyunGuo;YupeiWu;ZhipingZhang;
• 机 构: Tongji School of Phamarcy,Tongji Medical College,Huazhong University of Science &Technology,Wuhan 43
• 出 处: 2014年中国药物制剂大会——中国药学会药剂专业委员会年会、第六届亚洲阿登制药技术研讨会暨国际控释协会中国分会年会
• 发表日期: 2014年期

　　As the fourth leading cause of cancer death, hepatocellular carcinoma, its clinical treatment by chemotherapy is not satisfactory.Encapsulation of drugs within nanocarriers that selectively target hepatocellular carcinoma cells based on molecular oncology are constantly being developed recent years.Here, in order to mitigate side effects and enhance hepatic cancer cellular uptake, we deliver doxorubicin (DOX) by a tumor targeting peptide modified micelles with small size (13.0±0.8nm) and high encapsulation efficiencies (98.0%±1.0%).SP94 (SFSIIHTPILPLGGC) conjugate onto the surface of DOX encapsulated micelles exhibit greater affinity to human hepatocellular carcinoma than to A549, A2780 or MCF7cells in vitro.Compared with free DOX, the drug loaded micelles significantly prolonged the half-life of DOX (t1/2=51.3±0.5h) and inhibited tumor growth in vivo.The specific nanocarriers have great potential in the development of nanomedicine for hepatocellular carcinoma diagnosis and therapy.